Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Recommendation of “Hold” by Analysts

Bausch Health Cos Inc. (NYSE:BHC) has been given a consensus rating of “Hold” by the six research firms that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $8.50.

A number of equities analysts have recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Truist Financial upped their price target on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Barclays initiated coverage on Bausch Health Cos in a research report on Monday, December 8th. They set an “equal weight” rating and a $8.00 price objective for the company. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Raymond James Financial restated a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.64 on Thursday. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of 5.84 and a beta of 0.42. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 57.48. The business’s 50-day moving average price is $6.83 and its 200-day moving average price is $6.72. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $8.69.

Institutional Trading of Bausch Health Cos

A number of large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Bausch Health Cos by 6,661.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after acquiring an additional 3,106 shares during the last quarter. Camelot Portfolios LLC bought a new stake in Bausch Health Cos during the fourth quarter worth $59,000. Alpha Wealth Funds LLC bought a new position in Bausch Health Cos in the 2nd quarter valued at $65,000. Finally, Stratos Wealth Advisors LLC purchased a new stake in shares of Bausch Health Cos during the 2nd quarter valued at $67,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.